Direct and Indirect Costs to Employers of Patients With Systemic Lupus Erythematosus With and Without Nephritis

被引:61
作者
Carls, Ginger [1 ]
Li, Tracy [2 ]
Panopalis, Pantelis [3 ]
Wang, Shaohung
Mell, Amy G. [1 ]
Gibson, Teresa B. [1 ]
Goetzel, Ron Z. [4 ]
机构
[1] Thomson Healthcare, Hlth & Product Div, Ann Arbor, MI USA
[2] Bristol Myers Squibb Co, Global Outcomes Res, Princeton, NJ USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Emory Univ, Rollins Sch Publ Hlth, Inst Hlth & Product Studies, Atlanta, GA USA
关键词
RHEUMATOID-ARTHRITIS; US EMPLOYERS; TRI-NATION; HEALTH; DISABILITY; BURDEN; EPIDEMIOLOGY; PREDICTORS; SERVICE; ABSENCE;
D O I
10.1097/JOM.0b013e31818a405a
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives: To estimate the medical- and productivity-related cost burden of systemic lupus erythematosus (SLE) and SLE with nephritis in an employee Population. Methods: Using administrative data, annual costs were calculated for SLE Patients, a subset with nephritis, and a matched control group of Patients without SLE. These costs were compared with the cost. of other chronic conditions. Results: Mean annual medical expenditures and short term. disability costs for SLE Patients were $12,238 and $1184 greater (2005 dollars), respectively, than those of controls. Mean medical expenditures, for SLE/nephritis patients were $46,862 greater than for controls. When compared with other chronic health conditions faced by employees, SLE/nephritis was the most costly condition. Conclusions: SLE, Particularly with nephritis, is associated with substantial costs. Therapies that can better manage SLE may provide opportunities for savings to employees. (J Occup Environ Med. 2009,51:66-79)
引用
收藏
页码:66 / 79
页数:14
相关论文
共 27 条
[1]   Lupus nephritis [J].
Agrawal, N ;
Chiang, LK ;
Rifkin, IR .
SEMINARS IN NEPHROLOGY, 2006, 26 (02) :95-104
[2]  
[Anonymous], 2001, P 26 ANN SAS US GROU
[3]   Cost of treatment of childhood-onset systemic lupus erythematosus [J].
Brunner, HI ;
Sherrard, TM ;
Klein-Gitelman, MS .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2006, 55 (02) :184-188
[4]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[5]   The systemic lupus erythematosus Tri-nation Study:: absence of a link between health resource use and health outcome [J].
Clarke, AE ;
Petri, M ;
Manzi, S ;
Isenberg, DA ;
Gordon, C ;
Senécal, JL ;
Penrod, J ;
Joseph, L ;
St Pierre, Y ;
Fortin, PR ;
Sutcliffe, N ;
Goulet, JR ;
Choquette, D ;
Grodzicky, T ;
Esdaile, JM .
RHEUMATOLOGY, 2004, 43 (08) :1016-1024
[6]  
Clarke AE, 1999, J RHEUMATOL, V26, P1500
[7]   A CANADIAN STUDY OF THE TOTAL MEDICAL COSTS FOR PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS AND THE PREDICTORS OF COSTS [J].
CLARKE, AE ;
ESDAILE, JM ;
BLOCH, DA ;
LACAILLE, D ;
DANOFF, DS ;
FRIES, JF .
ARTHRITIS AND RHEUMATISM, 1993, 36 (11) :1548-1559
[8]   Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden [J].
Danchenko, N ;
Satia, J ;
Anthony, M .
LUPUS, 2006, 15 (05) :308-318
[9]  
Fisher LS, 2000, HEALTH SERV RES, V34, P1351
[10]  
GIBSON TB, J OCCUP ENV IN PRESS